2023-09-15 07:00:00
Phase II positive on Lyme for Valneva
The biotech vaccine candidate against Lyme disease, VLA15 obtained satisfactory results in its phase II in children and adolescents. In one month, with a booster dose, the drug enabled a strong immune response, as has already been observed in adults. Subject to phase III results, Valneva and his partner Pfizer hope to file regulatory applications with the FDA and EMA by 2026.
Trial halted for J&J macitentan
Johnson & Johnson (J&J) announced the termination of the phase III trial evaluating macitentan in patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) due to futility. This decision was taken, following the recommendation of the independent data monitoring committee. J&J has marketed this compound for pulmonary arterial hypertension under the name Opsumit since its first approval in 2013.
VOS INDICES
source
Phase II positive for Roche and Alnylam
Roche communicated the positive results of phase II of the zilebesiran, an RNAi being evaluated to treat hypertension in patients at high risk of cardiovascular disease. The drug candidate met the primary endpoint, demonstrating a significant reduction in systolic blood pressure, after three months of treatment, compared to placebo. The laboratory is developing this active ingredient with Alnylam since July 2023.
Selected for you
1694822774
#pipelines #Valneva #Roche